Free Trial

Paragon 28 (FNA) Competitors

$6.04
+0.07 (+1.17%)
(As of 12:20 PM ET)

FNA vs. IRTC, SLNO, RXST, NVCR, WRBY, INMD, ESTA, SILK, AORT, and BLFS

Should you be buying Paragon 28 stock or one of its competitors? The main competitors of Paragon 28 include iRhythm Technologies (IRTC), Soleno Therapeutics (SLNO), RxSight (RXST), NovoCure (NVCR), Warby Parker (WRBY), InMode (INMD), Establishment Labs (ESTA), Silk Road Medical (SILK), Artivion (AORT), and BioLife Solutions (BLFS). These companies are all part of the "medical equipment" industry.

Paragon 28 vs.

Paragon 28 (NYSE:FNA) and iRhythm Technologies (NASDAQ:IRTC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

iRhythm Technologies has a net margin of -24.50% compared to Paragon 28's net margin of -24.64%. Paragon 28's return on equity of -32.39% beat iRhythm Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Paragon 28-24.64% -32.39% -17.07%
iRhythm Technologies -24.50%-84.14%-19.29%

In the previous week, Paragon 28 had 15 more articles in the media than iRhythm Technologies. MarketBeat recorded 27 mentions for Paragon 28 and 12 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 0.25 beat Paragon 28's score of 0.10 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Paragon 28
3 Very Positive mention(s)
0 Positive mention(s)
22 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
iRhythm Technologies
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
4 Negative mention(s)
0 Very Negative mention(s)
Neutral

Paragon 28 has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Paragon 28, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Paragon 28$235.44M2.12-$57.53M-$0.65-9.28
iRhythm Technologies$537.09M3.42-$123.41M-$4.23-13.95

63.6% of Paragon 28 shares are owned by institutional investors. 15.3% of Paragon 28 shares are owned by company insiders. Comparatively, 0.7% of iRhythm Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Paragon 28 has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Paragon 28 presently has a consensus target price of $15.25, indicating a potential upside of 150.41%. iRhythm Technologies has a consensus target price of $112.40, indicating a potential upside of 90.51%. Given Paragon 28's stronger consensus rating and higher possible upside, analysts plainly believe Paragon 28 is more favorable than iRhythm Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Paragon 28
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
iRhythm Technologies
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

iRhythm Technologies received 369 more outperform votes than Paragon 28 when rated by MarketBeat users. However, 81.58% of users gave Paragon 28 an outperform vote while only 66.01% of users gave iRhythm Technologies an outperform vote.

CompanyUnderperformOutperform
Paragon 28Outperform Votes
31
81.58%
Underperform Votes
7
18.42%
iRhythm TechnologiesOutperform Votes
400
66.01%
Underperform Votes
206
33.99%

Summary

Paragon 28 beats iRhythm Technologies on 11 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FNA vs. The Competition

MetricParagon 28Surgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$500.20M$4.01B$5.46B$19.66B
Dividend YieldN/A28.47%4.33%3.49%
P/E Ratio-8.7425.52141.2527.64
Price / Sales2.1266.801,171.1319.73
Price / CashN/A38.1237.7020.32
Price / Book2.943.974.685.42
Net Income-$57.53M$57.18M$118.97M$981.00M
7 Day Performance14.64%2.83%2.93%1.67%
1 Month Performance-18.40%17.75%15.87%5.13%
1 Year Performance-34.31%38.20%29.89%27.77%

Paragon 28 Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FNA
Paragon 28
2.1961 of 5 stars
$6.04
+1.2%
$15.25
+152.5%
-35.0%$501.02M$235.44M-8.75343,000
IRTC
iRhythm Technologies
3.0394 of 5 stars
$59.00
+1.8%
$112.40
+90.5%
-30.6%$1.84B$537.09M-13.822,000Analyst Forecast
SLNO
Soleno Therapeutics
4.3374 of 5 stars
$54.62
+1.4%
$68.71
+25.8%
+122.1%$1.82BN/A-22.3930
RXST
RxSight
1.6631 of 5 stars
$49.22
-2.1%
$60.14
+22.2%
+107.6%$1.82B$115.18M-48.25220
NVCR
NovoCure
4.1135 of 5 stars
$16.21
+0.9%
$25.17
+55.3%
+13.0%$1.74B$549.96M-10.261,453Positive News
WRBY
Warby Parker
1.3158 of 5 stars
$15.77
+1.4%
$16.71
+6.0%
+12.7%$1.56B$719.93M-40.443,491
INMD
InMode
3.5419 of 5 stars
$16.57
-0.5%
$22.00
+32.8%
-19.8%$1.39B$416.63M9.52480Analyst Forecast
ESTA
Establishment Labs
2.3301 of 5 stars
$41.55
+0.7%
$58.83
+41.6%
+20.0%$1.14B$151.35M-13.36960Analyst Forecast
SILK
Silk Road Medical
2.1048 of 5 stars
$27.49
flat
$24.00
-12.7%
N/A$1.12B$177.13M-20.07410News Coverage
AORT
Artivion
2.1389 of 5 stars
$26.64
+1.7%
$30.00
+12.6%
+95.3%$1.11B$376.97M-126.861,500
BLFS
BioLife Solutions
1.8595 of 5 stars
$23.05
-1.7%
$26.67
+15.7%
+94.5%$1.06B$139.96M-13.64409Positive News

Related Companies and Tools


This page (NYSE:FNA) was last updated on 10/15/2024 by MarketBeat.com Staff
From Our Partners